Stay updated with breaking news from Paulk Audhya. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – ...
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro...
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 3,280,000 shares, a growth of 17.1% from the April 15th total of 2,800,000 shares. Currently, 14.0% of the shares of the company are sold […]
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today